NASDAQ:AXON - Axovant Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.30 +0.11 (+9.24 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$1.30
Today's Range$1.19 - $1.30
52-Week Range$0.93 - $6.59
Volume1.27 million shs
Average Volume1.45 million shs
Market Capitalization$158.96 million
P/E Ratio-0.63
Dividend YieldN/A
Beta1.21
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.19 per share

Profitability

Net Income$-221,570,000.00

Miscellaneous

Employees45
Market Cap$158.96 million
Next Earnings Date6/10/2019 (Estimated)
OptionableOptionable

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) released its quarterly earnings data on Thursday, February, 7th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). View Axovant Sciences' Earnings History.

When is Axovant Sciences' next earnings date?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Monday, June 10th 2019. View Earnings Estimates for Axovant Sciences.

What price target have analysts set for AXON?

6 analysts have issued 12-month price targets for Axovant Sciences' stock. Their predictions range from $3.00 to $7.00. On average, they anticipate Axovant Sciences' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 284.6% from the stock's current price. View Analyst Price Targets for Axovant Sciences.

What is the consensus analysts' recommendation for Axovant Sciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axovant Sciences.

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:
  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/12/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to the achievement of target price. Our price target of $7/share is based on an equally-weighted composite of: (a) $6.27/share, as a 35x multiple of taxed and diluted $2.30 discounted back to FY18 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $7.26/share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2018)

Has Axovant Sciences been receiving favorable news coverage?

Media coverage about AXON stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Axovant Sciences earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.

Are investors shorting Axovant Sciences?

Axovant Sciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,188,830 shares, an increase of 39.1% from the January 15th total of 3,010,613 shares. Based on an average daily trading volume, of 1,081,989 shares, the short-interest ratio is presently 3.9 days. Currently, 8.0% of the company's stock are sold short. View Axovant Sciences' Current Options Chain.

Who are some of Axovant Sciences' key competitors?

What other stocks do shareholders of Axovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axovant Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Novavax (NVAX), Trevena (TRVN), Canopy Growth (CGC), General Electric (GE), Check Cap (CHEK) and AVEO Pharmaceuticals (AVEO).

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 37)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 48)
  • Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 58)
  • Dr. David T. Hung, Scientific Advisor of Group (Age 61)
  • Dr. Fraser Wright, Chief Technology Officer

When did Axovant Sciences IPO?

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Axovant Sciences' major shareholders?

Axovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (6.71%), BlackRock Inc. (1.12%), Hudson Bay Capital Management LP (1.02%), Monashee Investment Management LLC (0.82%), Opaleye Management Inc. (0.47%) and CVI Holdings LLC (0.36%). Company insiders that own Axovant Sciences stock include David Hung, George Bickerstaff, Global Investors Lp Viking, Svf Investments (Uk) Ltd and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Which major investors are selling Axovant Sciences stock?

AXON stock was sold by a variety of institutional investors in the last quarter, including Connor Clark & Lunn Investment Management Ltd., BlackRock Inc. and Two Sigma Investments LP. View Insider Buying and Selling for Axovant Sciences.

Which major investors are buying Axovant Sciences stock?

AXON stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Monashee Investment Management LLC, Opaleye Management Inc., CVI Holdings LLC, Hound Partners LLC, Hudson Bay Capital Management LP, Geode Capital Management LLC and Zacks Investment Management. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, George Bickerstaff, Global Investors Lp Viking, Svf Investments (Uk) Ltd and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $1.30.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $158.96 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Axovant Sciences employs 45 workers across the globe.

What is Axovant Sciences' official website?

The official website for Axovant Sciences is http://www.axovant.com.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  619
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel